Role of Allogeneic Transplants in Hematologic Malignancies

Now Viewing

EP: 1.Role of Allogeneic Transplants in Hematologic Malignancies

EP: 2.Hematologic Malignancies and Transplant Options and Conditioning Regimens Used in Allo-HSCT

EP: 3.Supportive Care Measures for Patients Planning to Receive an Allogenic Transplant

EP: 4.Transplant Complications and Survival Outcomes

EP: 5.Clinical Trial Update: CTN Trial

EP: 6.Graft-versus-Host Disease Prophylaxis and Management

EP: 7.Patient Case Studies of GvHD

EP: 8.Emerging Cellular Therapies in Hematologic Malignancies

EP: 9.Transplant in the Elderly Population

EP: 10.Toxicity Assessment of Precision-Engineered Allo-HSCT

EP: 11.The Role of Allo-HSCT in Higher-Risk MDS

EP: 12.Investigational Allo-HSCT for Advanced Hematologic Malignancies

EP: 13.The Future of Allo-HSCT and Cellular Therapies

EP: 14.OncLive Peer Exchange on Allo-HSCT: Conclusion of Discussion

This is a video synopsis/summary of a Peer Exchange featuring Miguel-Angel Perales, MD; Nelli Bejanyan, MD; Amandeep Salhotra, MD; and Arpita Gandhi, MD, MS.

The discussion focuses on the role of allogeneic hematopoietic stem cell transplantation in hematologic malignancies, particularly acute myeloid leukemia and acute lymphoblastic leukemia (ALL). Despite the advent of novel therapies, allogeneic transplantation remains the only curative option for many patients with high-risk features. Data from the Center for International Blood and Marrow Transplant Research shows improved outcomes for ALL patients undergoing allogeneic transplantation over time. The increasing use of alternative donors has made it possible for most patients in need of transplantation to find a suitable donor.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.